<DOC>
	<DOC>NCT02290951</DOC>
	<brief_summary>This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)</brief_summary>
	<brief_title>A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>Key 1. Have documented CD20+ Bcell malignancy, with active disease not responsive to prior therapy, for whom no standard of care options exists, and for whom treatment with an antiCD20 antibody may be appropriate: 2. Must have had prior treatment with an antiCD20 antibody therapy 3. Must have at least one bidimensionally measurable lesion ≥1.5 cm) documented by CT scan. 4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 5. Life expectancy of at least 6 months 6. Adequate bone marrow function documented by: 1. Platelet counts ≥75 x 109/L 2. Hb level ≥9 g/dL 3. ANC ≥1 x 109/L 7. Adequate organ function 8. Willing and able to comply with clinic visits and studyrelated procedures 9. Provide signed informed consent Key 1. Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by nonprimary CNS NHL 2. History of or current relevant CNS pathology 3. Allogeneic stem cell transplantation 4. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). 5. Known hypersensitivity to both allopurinol and rasburicase. The information provided above is not intended to contain all considerations relevant to potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>